- Previous Close
1,157.85 - Open
1,229.00 - Bid --
- Ask --
- Day's Range
1,173.05 - 1,267.30 - 52 Week Range
1,031.05 - 1,592.00 - Volume
7,500,989 - Avg. Volume
905,389 - Market Cap (intraday)
683.226B - Beta (5Y Monthly) 0.54
- PE Ratio (TTM)
19.65 - EPS (TTM)
59.86 - Earnings Date May 23, 2025 - May 27, 2025
- Forward Dividend & Yield 4.50 (0.40%)
- Ex-Dividend Date Feb 20, 2024
- 1y Target Est
1,483.14
Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
www.aurobindo.com26,015
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: AUROPHARMA.NS
View MorePerformance Overview: AUROPHARMA.NS
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AUROPHARMA.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AUROPHARMA.NS
View MoreValuation Measures
Market Cap
672.48B
Enterprise Value
681.53B
Trailing P/E
19.36
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.22
Price/Book (mrq)
2.18
Enterprise Value/Revenue
2.24
Enterprise Value/EBITDA
9.88
Financial Highlights
Profitability and Income Statement
Profit Margin
11.29%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
309.22B
Net Income Avi to Common (ttm)
34.91B
Diluted EPS (ttm)
59.86
Balance Sheet and Cash Flow
Total Cash (mrq)
68.68B
Total Debt/Equity (mrq)
27.29%
Levered Free Cash Flow (ttm)
--